SMAD2 and Hodgkins lymphoma: Collectively, our data revealed several modes of BMP-pathway inhibition in HL, including overexpression of FSTL3 and downregulation of SMAD2 via genomic alterations, and inhibition of BMPs via overexpressing ETV3.